Safety of Chloroquine or Hydroxychloroquine Plus Azithromycin for the Treatment of COVID-19 Patients in Burkina Faso: An Observational Prospective Cohort Study.
Toussaint RouambaHoureratou BarryEsperance OuédraogoMarc Christian TahitaNobila Valentin YaméogoArmel PodaArnaud Eric DiendéréAbdoul-Salam OuedraogoInnocent ValeaAmariane M KonéCherileila ThiombianoIsidore TraoréZekiba TarnagdaSerge A SawadogoZakaria GansanéYibar KambiréIdrissa SanouFatou Barro-TraoréMaxime K DraboHalidou Tintonull nullPublished in: Therapeutics and clinical risk management (2021)
Hydroxychloroquine appeared to be well tolerated in treated COVID-19 patients in Burkina Faso. In the absence of a robust methodological approach that could generate a high level of scientific evidence, our results could at least contribute to guide health decisions that should be made based on different sources of scientific evidence including those from our study.